Raekiansyah Muhareva, Buerano Corazon C, Luz Mark Anthony D, Morita Kouichi
Department of Virology, Institute of Tropical Medicine, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.
Research and Biotechnology, St. Luke's Medical Center, Quezon City, Philippines.
Arch Virol. 2018 Jun;163(6):1649-1655. doi: 10.1007/s00705-018-3769-y. Epub 2018 Feb 10.
Dengue virus (DENV) infection is a major public health problem worldwide; however, specific antiviral drugs against it are not available. Hence, identifying effective antiviral agents for the prevention of DENV infection is important. In this study, we showed that the reportedly highly biologically active green-tea component epigallocatechin gallate (EGCG) inhibited dengue virus infection regardless of infecting serotype, but no or minimal inhibition was observed with other flaviviruses, including Japanese encephalitis virus, yellow fever virus, and Zika virus. EGCG exerted its antiviral effect mainly at the early stage of infection, probably by interacting directly with virions to prevent virus infection. Our results suggest that EGCG specifically targets DENV and might be used as a lead structure to develop an antiviral drug for use against the virus.
登革病毒（DENV）感染是全球主要的公共卫生问题；然而，目前尚无针对该病毒的特效抗病毒药物。因此，鉴定有效的抗病毒药物以预防登革病毒感染至关重要。在本研究中，我们发现据报道具有高生物活性的绿茶成分表没食子儿茶素没食子酸酯（EGCG）可抑制登革病毒感染，且不受感染血清型的影响，但对其他黄病毒，包括日本脑炎病毒、黄热病病毒和寨卡病毒，未观察到抑制作用或仅有轻微抑制。EGCG主要在感染早期发挥抗病毒作用，可能是通过直接与病毒粒子相互作用来预防病毒感染。我们的研究结果表明，EGCG特异性靶向登革病毒，可能作为开发抗该病毒的抗病毒药物的先导结构。
